alfuzosin has been researched along with Urinary Tract Diseases in 8 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy and safety of the selective alpha(1)-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, differentiating and bothersome symptoms in men with chronic prostatitis/chronic pelvic pain syndrome." | 9.12 | The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. ( Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G, 2006) |
| "To determine the efficacy and safety of the selective alpha(1)-blocker alfuzosin in men with lower urinary tract symptoms (LUTS) and painful ejaculation, compared with those with LUTS only, as painful ejaculation is one of the most prevalent, differentiating and bothersome symptoms in men with chronic prostatitis/chronic pelvic pain syndrome." | 5.12 | The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. ( Elhilali, M; Emberton, M; Nickel, JC; Vallancien, G, 2006) |
| "Tamsulosin has selectivity for the a alpha(1) and alpha(1d) receptor subtypes." | 2.42 | Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. ( Lowe, FC, 2004) |
| "dizziness and orthostatic hypotension)." | 2.40 | A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. ( Djavan, B; Marberger, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liguori, G | 1 |
| Trombetta, C | 1 |
| De Giorgi, G | 1 |
| Pomara, G | 1 |
| Maio, G | 1 |
| Vecchio, D | 1 |
| Ocello, G | 1 |
| Ollandini, G | 1 |
| Bucci, S | 1 |
| Belgrano, E | 1 |
| Permpongkosol, S | 1 |
| Krilad-O-Larn, S | 1 |
| Ratana-O-Larn, K | 1 |
| Lowe, FC | 1 |
| Elhilali, MM | 1 |
| Nickel, JC | 1 |
| Elhilali, M | 1 |
| Emberton, M | 1 |
| Vallancien, G | 1 |
| Witjes, WP | 1 |
| de la Rosette, JJ | 1 |
| Zerbib, M | 1 |
| Vignoli, GC | 1 |
| Geffriaud, C | 1 |
| Debruyne, FM | 1 |
| Wijkstra, H | 1 |
| Djavan, B | 1 |
| Marberger, M | 1 |
| Chess-Williams, R | 1 |
4 reviews available for alfuzosin and Urinary Tract Diseases
| Article | Year |
|---|---|
Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Hum | 2004 |
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Huma | 2006 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizzines | 1999 |
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
Topics: Adrenergic alpha-Antagonists; Humans; Hypertension; Male; Prostatic Hyperplasia; Quinazolines; Sulfo | 2002 |
3 trials available for alfuzosin and Urinary Tract Diseases
1 other study available for alfuzosin and Urinary Tract Diseases
| Article | Year |
|---|---|
Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow.
Topics: Adrenergic alpha-Antagonists; Computer Simulation; Humans; Male; Models, Biological; Observer Variat | 1998 |